News | August 15, 2022
Arbitrator rules in favor of Daiichi Sankyo in dispute with Seagen
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
The product will be manufactured at Lupin’s facility in Goa, India.
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
MeitY will provide technical support for digitalisation of the Ayush Sector under the Ayush Grid project for a period of three years
Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces
The vaccine has been developed by the National Equine Research Center, Hisar (Haryana) in collaboration with the Indian Veterinary Research Institute, Izzatnagar (Bareilly)
Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Subscribe To Our Newsletter & Stay Updated
